Dr. Farrugia is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.
About Mark Farrugia
Positions
- Clinical Assistant Professor of Oncology, Radiation Medicine
- Staff Physician
- Department of Radiation Medicine
Background
Education and Training:
- 2011-2015 - PhD - Cancer Cell Biology, West Virginia University, Morgantown, WV
- 2009-2017 - MD - West Virginia University, Morgantown WV
Residency:
- 2018-2022 - Radiation Oncology, University at Buffalo, Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY
- 2017-2018 - Transitional Year, West Virginia University, Morgantown, WV
Board Certification:
- American Board of Radiology - Board Eligible
Honors & Awards:
- 2021-2022 - Chief Resident
- 2021 - Roentgen Resident/Fellow Research Award
- 2020 - Roentgen Resident/Fellow Research Award
- 2017 - Resident of the Month (three nominations)
- 2011 - Recognition of Academic Excellence
- 2009 -Merck Index Award for Excellence in Chemistry
Featured on Cancer Talk
Publications
Mark Farrugia, Han Yu, Sung Jun Ma, Austin Iovoli, Saraswati Pokharel, Umesh C. Sharma, Simon Fung-Kee-Fung, Nadia Malik, Anurag K. Singh, and Harish Malhotra. Right atrial dose is associated with worse outcome in patients undergoing definitive stereotactic body radiation therapy for central lung tumors. Cancers 2022. DOI: 10.3390/cancers14061391
Mark Farrugia, Han Yu, Gregory M Videtic, Kevin L Stephans, Sung Jun Ma, Adrienne Groman, Jeffrey A Bogart, Jorge A Gomez-Suescun, Anurag K. Singh. A Principal Component of Quality of Life Measures Is Associated with Survival:
Validation in a Prospective Cohort of Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy. Cancers 2021. Epub ahead of print
Farrugia MK, Ma SJ, Hennon MW, Nwogu CE, Dexter EU, Picone AL, Demmy TL, Yendamuri SS, Yu H, Fung-Kee-Fung S, Gomez-Suescun JA, Singh AK and Malhotra H. Exceeding radiation dose to volume parameters for the proximal airways with stereotactic body radiation therapy is more likely for ultracentral lung tumors and associated with worse outcome. Cancers. 2021. Epub ahead of print
Farrugia MK, Yu H, Ma SJ, Iovoli AJ, Attwood K, Wooten KE, Arshad H, Gupta V, McSpadden RP, Kuriakose MA, Markiewicz MR, Chan JM, Hicks WL , Platek ME, Ray AD, Repasky EA. Singh AK. A Principal Component of Quality of Life Measures is Associated with Survival for Head and Neck Cancer Patients Treated with Radiation Therapy. Cancers 2021, 13(5), 1155
Farrugia MK, Ma SJ, Mattson DM, Flaherty L, Repasky EA, Sing AK. Concurrent β-blocker use is associated with improved outcome in esophageal cancer patients who undergo chemoradiation: A retrospective matched pair analysis.
American Journal of Clinical Oncology. October 09, 2020 - Volume Publish Ahead of Print - Issue - doi: 10.1097/COC.0000000000000768